Daclatasvir
Daclatasvir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
- Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HCV genotypes 2, 4.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
- Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HCV genotypes 2, 4.
There's more to see -- the rest of this entry is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved